Novavax (NVAX) Says Phase 3 Trial of RSV F Vaccine for Infants via Maternal Immunization Will Continue; Provides Update on Phase 1/2 Trial of NanoFlu Vaccine

Go back to Novavax (NVAX) Says Phase 3 Trial of RSV F Vaccine for Infants via Maternal Immunization Will Continue; Provides Update on Phase 1/2 Trial of NanoFlu Vaccine

Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine

December 18, 2017 4:33 PM EST

RSV F Vaccine informational analysis completed in fourth quarter of 2017RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrolleesFiling of RSV F Vaccine BLA anticipated by late 2019NanoFlu Vaccine data package to be completed and released in February 2018

GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M adjuvant (NanoFlu).... More